Industries · B2B healthcare · Biotech

A biotech marketing agency with reproducible results

Marketing that scientists don't roll their eyes at, for biotech and TechBio companies selling platforms and pipelines to pharma R&D.

Senior-led, every claim reviewed by your scientists, 30-day cancellation notice. Your first call is with a co-founder.

10,000+
organic engagements within weeks of first campaigns, for Cradle's protein-design platform (published case study). More client proof is public on our customers page.
Biotech and adjacent healthcare clients

The TechBio market in four numbers

31
AI-discovered assets in clinical phases in 2025 (The State of Marketing in Health Tech, TGS, 2026)
30+
pharma contracts signed with TechBio companies in 2025 (Health Tech Report)
150+
new TechBio companies founded in a single year (Health Tech Report)
~50
pharma companies that matter globally; a burned bridge is not replaceable (Health Tech Report)
The job

Why biotech marketing needs a different approach

Standard playbooks assume buyers who respond to persuasion. Your buyers respond to data.

Your buyers are scientists

Building credibility is now a top priority for 67% of scientific-audience companies, up from 22% in 2021 (AZoNetwork). Scientists check the literature before they take a call.

Lean or no marketing team

The most common marketing department in scientific companies runs two to five people (AZoNetwork, 2025); many platform biotechs run none, and the CEO reviews every slide.

Evaluations run six to 18 months

Platform sales into pharma take six to 18 months and often start as paid pilots (Compound VC). Research institutes decide faster, at far smaller deal sizes.

Credibility is earned, not claimed

Roughly 50 pharma companies matter globally, and 30+ TechBio contracts were signed in all of 2025 (Health Tech Report). Every buyer talks to every other buyer.

Problems we solve

Problems we solve for biotech companies

First-call sentences from founders and business leads, lightly anonymized.

“Our pipeline is whoever the CEO met at BIO last year.”
What we hear
ABM against a named list of pharma accounts, and each conference run as a campaign with a target meeting list.
What we do
“The same deck has to raise our round and open pharma doors.”
What we hear
One narrative for the raise and the partnering conversation, cut in registers for scientists, BD teams and investors.
What we do
“Everyone here can explain the science; nobody owns a pipeline number.”
What we hear
‍A Head of Growth runs the account and reports engaged accounts and meetings from month three.‍
What we do
“Consultants gave us strategy decks. We needed someone to run the work.”
What we hear
We run the work ourselves: content, ABM, conferences and the founder channel.
What we do
“Our best data sits under CDA, and the website has to sell without it.”
What we hear
We sell with what is already public: papers, preprints and posters turned into readable assets for BD and investors.
What we do
“Our scientists won't post on LinkedIn, and the company page talks to nobody.”
What we hear
We build the founder's channel for them: their thinking, their voice, their sign-off, and the accounts that engage flagged to sales each week.
What we do

Lab instruments, tools and CRO services are adjacent but different work. This page, and this team, are for platform and therapeutics companies.

Approach

Biotech digital marketing built on scientific credibility

Five disciplines, one Head of Growth, and your scientists holding review on everything public.

Scientific content your team reviews

Drafts reach your scientists at outline stage, so review shapes a piece instead of killing it. Published papers, preprints and posters become readable assets for BD and investors, and nothing goes out without a technical sign-off.

ABM into named pharma accounts

The buyer list is finite: therapeutic-area teams, computational groups and BD&L contacts at the majors, plus the mid-pharma tier that moves faster. Campaigns run against that named list and report accounts engaged, not clicks bought.

Partnering-conference strategy

BIO logged 66,308 partnering meetings in 2025, and the calendar from JPM to BIO-Europe is where biotech deals start. We treat each conference as a campaign: a target meeting list, pre-booked outreach, follow-up nurture.

Investor-facing narrative

One narrative serves the raise and the partnering conversation, because pharma validation moves your round and a strong round steadies pharma's confidence. The story is written once, then cut in registers for scientists, BD teams and investors.

LinkedIn for founders

Scientists follow people, not company pages. We build the founder's channel on their actual thinking: drafted to an outline, written in their voice, approved by them, with engaged accounts flagged to sales every week.

The rule we work by

Nothing ships that your scientists wouldn't put their name under.

We work pay-as-you-go on hourly rates, with a 30-day cancellation notice. Biotech engagements usually start narrow, one audience and one channel pair, then widen as the data earns it.

Results

Results from the biotech practice

Biotech
For Cradle, AI protein design at Series B in Amsterdam and Zurich, 30%+ of webinar signups came from target accounts.
60+
high-potential sales interactions flagged per quarter
350+
webinar signups
Health tech
Coforix sells generative AI for hospital administration. It came to us with a certified product and no marketing in place, and ran its first ABM program with us over six to seven months.
165
high-intent target contacts engaging on LinkedIn
27
engaged leads ready for sales follow-up

Every figure in this section sits on a published case study, Cradle's or Coforix's, with the method on the page.

What do they say?

We like to let our customers do the talking.

Your journey

Your first 90 days,
week by week

We don’t work from a template. Your Head of Growth builds the plan around your science, your pharma buyers and the partnering calendar you sell into. The cards below show one example for a TechBio company.

Kick off
●
Day 0

We meet your founders, whoever leads business development and one or two of your scientists, get access to the website, CRM and analytics, and agree what counts as progress with a pharma account: a first meeting, a technical review or a paid pilot.

Onboarding
KPI alignment
Ysabel CamusBerk Kalyoncu
Full audit
●
Weeks 1-2

We talk to a few of your pharma contacts and the scientists who evaluated you, go through partnering conversations that stalled, and audit the website, search and AI-search visibility, LinkedIn and CRM tracking.

Partner interviews
Website and search
CRM and tracking
Michaela RiesBerk KalyoncuYsabel Camus
Strategy & workshops
●
Weeks 3-4

Workshops with your founders, science leads and BD team. The result is a plan written for your company: one story that works for pharma and for investors, a review process your scientists agree to, and a named list of pharma accounts by therapeutic area.

Positioning
Review process
Pharma accounts
Ysabel CamusMichaela RiesBerk Kalyoncu
Quick wins
●
Weeks 4-5

We fix tracking and the partnering inquiry form, stop ad spend that reaches students and job seekers, and add your published papers and posters to the pages buyers visit first.

Tracking
Ad fixes
Publications
Berk KalyoncuAlexandru Cojuhari
Platform pages go live
●
Week 6+

New platform and pipeline pages go onto the website, with the data, methods and validation work a pharma scientist checks before agreeing to a call.

Platform pages
Pipeline pages
Validation data
Michaela RiesDaniela GutuAlexandru Cojuhari
Scientific content
●
Week 6+

Your scientists see every piece at outline stage and again before it goes out. We turn papers, preprints and posters into explainers and webinars that your BD team can forward to a pharma contact.

Scientist review
Explainers
Webinars
Michaela RiesYsabel Camus
Named-account campaigns
●
Week 6+

LinkedIn campaigns run against the agreed list of pharma accounts, with different messages for the therapeutic-area lead, the computational group and business development. Each week your BD team gets the accounts that engaged.

Pharma accounts
LinkedIn
Weekly account list
Berk KalyoncuYsabel Camus
Partnering events
●
Week 6+

For the next partnering event on your calendar, such as BIO-Europe or JPM week, we build the target meeting list, book meetings ahead of time and prepare the follow-up for the weeks after.

Target meetings
Pre-booked outreach
Follow-up
Ysabel CamusDaniela Gutu
First pipeline report
●
Month 3

Your founders and board get one report: pharma accounts engaged, meetings held, evaluations started and where each account stands. We don’t promise signed partnerships inside 90 days, because pharma evaluations take six to 18 months.

Accounts engaged
Meetings
Evaluations
Ysabel CamusBerk Kalyoncu
?
After day 90

Your Head of Growth reviews the report with your founders and plans the next quarter around the conference calendar. More of the budget goes to the accounts that moved, and the rest is scaled back.

Review with you
Plan adjusted

One healthcare practice, segment by segment

Biotech is one of five segments in our B2B healthcare practice; the hub maps the other four.

You are here

Biotech and TechBio

Platforms, AI-for-biology and therapeutics developers selling to pharma R&D, scientists and investors. Evidence bar: peer-reviewed credibility. Client: Cradle.

Health tech

Health tech and healthcare software

Software and AI sold to hospitals and health systems through committee buying. Buyer: CIOs, CMIOs, clinical operations. Client: Coforix. Covered on the hub.

The hub

All of B2B healthcare

The parent page maps all five segments, from medtech to diagnostics, with the buyer, regulation and sales motion for each.

Who you'd be working with

The people below write, plan and report, with no junior handoff after the signature.

Team
Ysabel Camus
Ysabel Camus
Head of Growth
James Eisner, Head of Growth at The Growth Syndicate
James Eisner
Head of Growth
Michaela Ries
Michaela Ries
SEO / GEO Lead
Berk Kalyoncu
Berk Kalyoncu
Performance Specialist
Daniela Gutu
Daniela Gutu
Graphic Designer
Alexandru Cojuhari
Alexandru Cojuhari
Front End & Web Developer
André Antunes
André Antunes
RevOps & AI Lead
Daniel Bilici
Daniel Bilici
Sr. Growth Marketing Manager
Read our report · The State of Marketing in Health Tech

What 2026 looked like for TechBio and pharma partnering

The State of Marketing in Health Tech 2026 report cover

The report's TechBio chapter covers who signs platform deals, where budget sits inside pharma, and why digital health teams don't hold the money.

12
sections, buying committees to channel choice
6
practitioner interviews behind the findings
3
rounds of desk research
Read the report
No form between you and it; the pharma-budget chapter is the one to read first.
FAQ

Questions buyers ask a biotech marketing agency

Where we work

Amsterdam and New York, covering EU biotech hubs and the US coasts. Cradle runs from Amsterdam and Zurich.

What does a biotech marketing agency do?
What's the difference between biotech, life sciences and pharma marketing?
How do you generate B2B leads for a biotech company?
Can a biotechnology marketing agency really understand our science?
How do you market to pharma when the budget sits with brand teams?
How long does biotech marketing take to show pipeline?
Do you help with investor and fundraising messaging?
How does pricing work?

Your first call is with a co-founder

The call is 30 minutes with the founder who has the most experience in your industry.

Book a 30-minute call